Neurocrine’s Diurnal presents Phase 3 data of Efmody in adrenal hyperplasia

Neurocrine Biosciences company Diurnal will present new post hoc analyses of Phase 3 extension study data for modified-release hydrocortisone – approved as Efmody in U.K. and E.U. being investigated as a treatment for adults with congenital adrenal hyperplasia – CAH -, at ENDO 2023 June 15-18 in Chicago. Diurnal developed this modified-release formulation of hydrocortisone, which has been specifically designed to replicate the natural circadian release of cortisol. After 24 months of treatment, median daily hydrocortisone dose was reduced from 30 mg to 20 mg. The number of patients achieving lower androgen levels while receiving less than or equal to25 mg of hydrocortisone per day increased significantly, with 48 percent of the subjects achieving 17-OHP levels less than36 nmol/L compared with 31 percent at baseline.